Biomunex is a biopharmaceutical specializing in the discovery and development of innovative therapeutic approaches based on solid data and biological and clinical evidence to address unmet medical needs in oncology.

Biomunex has developed BiXAb®, a robust, next-generation, plug-and-play technology platform for bi- and multi-specific antibodies, which enables the generation of bispecific antibodies from any pair of monoclonals in a simple, rapid, and cost-effective manner, has been validated with licensing agreements and collaborations with the pharmaceutical and biotechnology industry, including Ipsen, Sanofi, and Onward Therapeutics.

Biomunex is the first company to develop a cancer immunotherapy approach, the MAIT engagers, that uses bispecific antibodies to specifically target, engage, and redirect MAIT cells, a subset of T cells naturally present throughout the body, particularly in mucosal and barrier tissues, to kill cancer cells for the treatment of solid tumors.